SKB 410
Alternative Names: SKB-410Latest Information Update: 30 Jun 2023
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Jun 2023 Preclinical trials in Solid tumours in China (Unspecified)
- 18 Jun 2023 Sichuan Kelun Pharmaceutical Research Institute plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease) in China (Unspecified) (NCT05906537)